Barbara Bispham - Jun 13, 2025 Form 3 Insider Report for CRESCENT BIOPHARMA, INC. (CBIO)

Role: General Counsel and Corporate Secretary. Exhibit 24 - Power of Attorney
Signature: /s/ Barbara Bispham
Stock symbol: CBIO
Transactions as of: Jun 13, 2025
Transactions value $: $0
Form type: 3
Date filed: 6/30/2025, 04:16 PM
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Bispham Barbara Harlin	General Counsel and Corporate Secretary. Exhibit 24 - Power of Attorney	C/O CRESCENT BIOPHARMA, INC., 300 FIFTH AVENUE, WALTHAM	/s/ Barbara Bispham	2025-06-30	0002075230

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
holding	CBIO	Stock Option (Right to Buy)							Jun 13, 2025	Ordinary Shares	106K	$6.16	Direct	F1, F2, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Effective as of June 13, 2025 (the "Effective Time"), (i) a wholly-owned subsidiary of GlycoMimetics, Inc. ("GlycoMimetics") merged with and into Crescent Biopharma, Inc. ("Pre-Merger Crescent") with Pre-Merger Crescent continuing as a wholly owned subsidiary of GlycoMimetics and the surviving corporation of the merger (the "First Merger"), (ii) immediately thereafter, Pre-Merger Crescent merged with and into a second wholly-owned subsidiary of GlycoMimetics ("Second Merger Sub"), with Second Merger Sub being the surviving entity of the merger under the name Crescent Biopharma Operating Company, LLC (the "Second Merger" and, together with the First Merger, the "Merger"). At the Effective Time, GlycoMimetics changed its name to "Crescent Biopharma, Inc." (hereinafter, the "Issuer").
F2	This Form gives effect to the Issuer's completion of a conversion from a corporation organized under the laws of the State of Delaware (the "Delaware Corporation") to an exempted company incorporated under the laws of the Cayman Islands (the "Cayman Company"), effective as of June 16, 2025. In connection therewith, each outstanding option or right to acquire shares of common stock of the Delaware Corporation continued in existence in the form of and automatically became an option or right to acquire an equal number of ordinary shares of the Cayman Company under the same terms and conditions.
F3	Represents options to purchase the Issuer's ordinary shares received by the Reporting Person in the Merger in exchange for options of Pre-Merger Crescent held by the Reporting Person prior to the Merger. This option will vest as to 25% on January 13, 2026 and in equal monthly installments thereafter through January 13, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.

Remarks:

General Counsel and Corporate Secretary. Exhibit 24 - Power of Attorney